- Home
- OPTN vs QNCX Comparison
OPTN vs QNCX Comparison
Compare OPTN & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- QNCX
- Stock Information
- Founded
- OPTN 2010
- QNCX 2012
- Country
- OPTN United States
- QNCX United States
- Employees
- OPTN N/A
- QNCX N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPTN Health Care
- QNCX Health Care
- Exchange
- OPTN Nasdaq
- QNCX Nasdaq
- Market Cap
- OPTN 55.4M
- QNCX 62.0M
- IPO Year
- OPTN 2017
- QNCX 2019
- Fundamental
- Price
- OPTN $9.14
- QNCX $1.36
- Analyst Decision
- OPTN Hold
- QNCX Strong Buy
- Analyst Count
- OPTN 3
- QNCX 5
- Target Price
- OPTN $9.00
- QNCX $8.00
- AVG Volume (30 Days)
- OPTN 166.1K
- QNCX 123.0K
- Earning Date
- OPTN 03-26-2025
- QNCX 03-24-2025
- Dividend Yield
- OPTN N/A
- QNCX N/A
- EPS Growth
- OPTN N/A
- QNCX N/A
- EPS
- OPTN N/A
- QNCX N/A
- Revenue
- OPTN $78,226,000.00
- QNCX N/A
- Revenue This Year
- OPTN $13.42
- QNCX N/A
- Revenue Next Year
- OPTN $38.54
- QNCX N/A
- P/E Ratio
- OPTN N/A
- QNCX N/A
- Revenue Growth
- OPTN 10.20
- QNCX N/A
- 52 Week Low
- OPTN $4.82
- QNCX $0.51
- 52 Week High
- OPTN $22.50
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- OPTN 81.15
- QNCX 44.67
- Support Level
- OPTN $9.12
- QNCX $1.30
- Resistance Level
- OPTN $9.35
- QNCX $1.42
- Average True Range (ATR)
- OPTN 0.25
- QNCX 0.09
- MACD
- OPTN 0.35
- QNCX 0.00
- Stochastic Oscillator
- OPTN 88.99
- QNCX 35.00
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.